Recombinant activated factor VII as an adjunctive therapy for bleeding control in severe trauma patients with coagulopathy: subgroup analysis from two randomized trials

Table 4 Transfusion requirements during the 48 hours after the first dose of trial drug in the placebo and rFVIIa groups

	Placebo group		rFVIIa group
	n	Median (range)	n	Median (range)	Differences in medians	Estimated reduction: median of differences (95% CI)^a	P value^b
RBC (units)
All patients	76	6.5 (0–41)	60	4.4 (0–39.9)	2.1	2.6 (0.1; 5.1)	0.02
Alive at 48 hours	65	6.6 (0–41)	48	2.9 (0–20)	3.7	3.5 (1.7; 5.7)	<0.001
FFP (ml)
All patients	60	1,360 (0–6,912)	42	705 (0–9,000)	655	600 (0.00; 1,320)	0.04
Alive at 48 hours	54	1,400 (0–6,912)	35	660 (0–9,000)	740	800 (250.0; 1,420)	0.001
Platelets (ml)
All patients	72	300 (0–1,500)	55	147 (0–1,200)	153	50 (0; 250)	0.09
Alive at 48 hours	62	300 (0–1,500)	46	100 (0–900)	200	50 (0; 250)	0.01

^aThe Hodges-Lehman shift with 95% CI. Patients who died within 48 hours were assigned the highest rank for the Wilcoxon-Mann-Whitney test and the Hodges-Lehman estimate. ^bTwo-sided Wilcoxon-Mann-Whitney rank sum test. CI, confidence interval; FFP, fresh frozen plasma; RBC, red blood cell; rFVIIa, recombinant activated factor VII.

ISSN: 1364-8535